William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating on April 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors related to Cardiff Oncology’s promising developments in cancer treatment. The recent preclinical studies presented at the American Association for Cancer Research (AACR) annual meeting highlighted the potential of onvansertib, a small-molecule inhibitor targeting polo-like kinase 1 (PLK1), which is often overexpressed in various cancers. The research demonstrated that onvansertib, when used in conjunction with carboplatin, showed encouraging results in endometrial cancer cell lines.
These findings suggest a strong rationale for further exploring the onvansertib and carboplatin combination as a treatment regimen for endometrial cancer. The promising preclinical data supports the potential efficacy of this combination, providing a basis for optimism about Cardiff Oncology’s future prospects in the oncology field. Hsieh’s recommendation reflects confidence in the company’s strategic direction and the innovative nature of its cancer therapies.